Just realised I posted on wrong community (LoL.) The AZD5069 and enzaltutamide trial has been widely reported in the UK press. Very small sample size to check the concept but it targets white myeloid blood cells which apparently can fuel tumour growth. The drug combo works is designed to block the CXCR2 receptor and try to switch of the growth. Around 24% in a small sample showed either tumour reduction or blocked growth. De Bono and Prostate Cancer UK (which I support) are involved. The trial was conducted with men who had exhausted other treatment options. Still seems early days before we see it mainstream. We really need to find a way of safely fast tracking promising developments.
Best wishes to all on here.